Michael McCleod
About
Michael McCleod is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology.
According to data from OpenAlex, Michael McCleod has authored 44 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Michael McCleod's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Michael McCleod is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Michael McCleod collaborates with scholars based in United States, Italy and Germany. Michael McCleod's co-authors include Taral Patel, Fairooz F. Kabbinavar, William Novotny, J. Randolph Hecht, John Hamm, R. Mass, Joseph J. Schulz, B. Nelson, Niels Reinmuth and Maen Hussein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
In The Last Decade
Michael McCleod
42 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael McCleod United States | 17 | 2.5k | 1.7k | 410 | 341 | 276 | 44 | 3.0k | ||
| Davey B. Daniel United States | 19 | 2.2k 0.9× | 2.1k 1.2× | 538 1.3× | 362 1.1× | 688 2.5× | 82 | 3.3k | ||
| Jerome H. Goldschmidt United States | 16 | 1.3k 0.5× | 1.0k 0.6× | 356 0.9× | 241 0.7× | 160 0.6× | 68 | 1.9k | ||
| Alexander I. Spira United States | 10 | 2.2k 0.9× | 1.3k 0.8× | 228 0.6× | 636 1.9× | 384 1.4× | 19 | 2.5k | ||
| G. Robinet France | 23 | 2.1k 0.8× | 2.3k 1.4× | 522 1.3× | 102 0.3× | 325 1.2× | 110 | 3.0k | ||
| Vera Gorbounova Russia | 13 | 2.2k 0.9× | 1.8k 1.1× | 617 1.5× | 151 0.4× | 354 1.3× | 23 | 3.2k | ||
| Daniel Waterkamp United States | 21 | 3.5k 1.4× | 1.9k 1.1× | 311 0.8× | 813 2.4× | 530 1.9× | 39 | 3.9k | ||
| Dominique Grunenwald France | 28 | 1.3k 0.5× | 2.1k 1.3× | 299 0.7× | 259 0.8× | 281 1.0× | 86 | 3.3k | ||
| Vinod Ganju Australia | 24 | 2.0k 0.8× | 906 0.5× | 655 1.6× | 144 0.4× | 447 1.6× | 94 | 2.7k | ||
| Venice Archer United Kingdom | 9 | 3.6k 1.4× | 3.6k 2.1× | 919 2.2× | 276 0.8× | 663 2.4× | 16 | 4.6k | ||
| Shelley Coleman United States | 7 | 2.8k 1.1× | 1.9k 1.1× | 399 1.0× | 599 1.8× | 387 1.4× | 10 | 3.2k |
Countries citing papers authored by Michael McCleod
Since
Specialization
Citations
This map shows the geographic impact of Michael McCleod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael McCleod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael McCleod more than expected).
Fields of papers citing papers by Michael McCleod
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael McCleod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael McCleod. The network helps show where Michael McCleod may publish in the future.
Co-authorship network of co-authors of Michael McCleod
This figure shows the co-authorship network connecting the top 25 collaborators of Michael McCleod. A scholar is included among the top collaborators of Michael McCleod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael McCleod. Michael McCleod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2020). Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. Clinical Lung Cancer. 22(1). 6–15.e4.
2.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937.
3.
Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2018). nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. Annals of Oncology. 29. viii749–viii750.
4.
Waterhouse, David, Leora Horn, Craig H. Reynolds, et al.. (2018). Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. Cancer Chemotherapy and Pharmacology. 81(4). 679–686.
5.
Hainsworth, John D., David Waterhouse, Kent C. Shih, et al.. (2018). Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer. 118. 6–12.
6.
Salgia, Ravi, Michael McCleod, John R. Stille, et al.. (2017). Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Investigational New Drugs. 35(3). 334–344.
7.
Thomas, Michael, David R. Spigel, Robert M. Jotte, et al.. (2017). <em>nab</em>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. PubMed. Volume 8. 207–216.
8.
Spigel, David R., Lee S. Schwartzberg, David Waterhouse, et al.. (2017). P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153. Journal of Thoracic Oncology. 12(1). S1287–S1288.
9.
Salgia, Ravi, John R. Stille, Michael McCleod, et al.. (2017). A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer. Lung Cancer. 105. 7–13.
10.
Johnson, Melissa L., Volker Wacheck, Maen Hussein, et al.. (2016). A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi441–vi441.
11.
Planchard, David, Takashi Yokoi, Michael McCleod, et al.. (2016). A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. Clinical Lung Cancer. 17(3). 232–236.e1.
12.
Bendell, Johanna C., Ahmed Zakari, David Waterhouse, et al.. (2016). A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. Cancer Investigation. 34(5). 213–219.
13.
Spigel, David R., Johanna C. Bendell, Michael McCleod, et al.. (2011). Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer. Clinical Colorectal Cancer. 11(1). 45–52.
14.
Yardley, Denise A., Michael McCleod, Fred Schreiber, et al.. (2010). A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer. Cancer Investigation. 28(9). 925–931.
15.
Dudek, Arkadiusz Z., Timothy Larson, Michael McCleod, et al.. (2008). Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 394–399.
16.
Lynch, Thomas J., Taral Patel, Luke Dreisbach, et al.. (2007). B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S340–S341.
17.
Treat, Joseph, Philip Bonomi, Michael McCleod, et al.. (2006). Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial. Lung Cancer. 53(1). 77–83.
18.
Kabbinavar, Fairooz F., Joseph J. Schulz, Michael McCleod, et al.. (2005). Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 23(16). 3697–3705.
19.
Dosoretz, Daniel E., James H. Rubenstein, Michael J. Katin, et al.. (1998). Small-Cell Lung Carcinoma. American Journal of Clinical Oncology. 21(4). 333–337.
20.
Rubenstein, James H., Daniel E. Dosoretz, Michael J. Katin, et al.. (1995). Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung. International Journal of Radiation Oncology*Biology*Physics. 33(2). 329–337.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Jerome H. Goldschmidt Breakdown of academic impact, for papers by Alexander I. Spira Breakdown of academic impact, for papers by G. Robinet Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Daniel Waterkamp Breakdown of academic impact, for papers by Dominique Grunenwald Breakdown of academic impact, for papers by Vinod Ganju Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Shelley Coleman